Osteoporosis and Bone Mineral Density: DEXA Scans, Calcium, and Fall Prevention
Osteoporosis is a systemic skeletal disorder characterized by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue, leading to bone fragility and heightened fracture risk. Explore the cellular biology of osteoclast/osteoblast remodeling, dual-energy X-ray absorptiometry (DEXA) T-score interpretation, FRAX fracture risk algorithms, anti-resorptive vs. anabolic bone medications, and progressive resistance loading.
Hands-free audio narration
This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.
Quick Summary & Key Findings
Osteoporosis is diagnosed via DEXA scan showing a T-score ≤ -2.5 (or the occurrence of a fragility fracture). First-line pharmacological management utilizes anti-resorptive Bisphosphonates (Alendronate, Zoledronic acid) or RANKL inhibitors (Denosumab), or bone anabolic agents (Teriparatide, Romosozumab) for severe disease, combined with Calcium (1,200 mg/day), Vitamin D3 (1,000–2,000 IU/day), and weight-bearing exercise.
In geriatric medicine and bone health, osteoporosis is known as the 'silent thief' because bone loss occurs continuously without pain or symptoms until a sudden, devastating fragility fracture occurs. Worldwide, 1 in 3 women and 1 in 5 men over the age of 50 will experience an osteoporotic fracture in their remaining lifetime.
Bone is not an inert scaffold; it is a highly active, dynamic living tissue undergoing continuous **bone remodeling**. Specialized cells called osteoclasts resorb old, micro-damaged bone, while osteoblasts synthesize new collagen matrix and mineralize it with calcium hydroxyapatite crystals.
Following menopause (with the loss of estrogen's protective suppression of osteoclasts) and during normal aging, osteoclastic bone resorption outpaces osteoblastic bone formation, converting dense trabecular bone into porous, fragile honeycomb structures.
Preventing osteoporotic hip and vertebral compression fractures requires early DEXA screening, optimized bone nutrition, and evidence-based pharmacotherapies.
Bone Remodeling Cellular Biology & Diagnostic T-Scores
Pharmacological Classes for Osteoporosis Management
| Medication Class | Key Medications | Mechanism of Action | Clinical Considerations & Dosing Rules |
|---|---|---|---|
| Oral Bisphosphonates (Anti-Resorptive) | Alendronate (Fosamax), Risedronate | Binds hydroxyapatite crystals and inhibits osteoclast farnesyl pyrophosphate synthase. | Take first thing in the morning on an empty stomach with a full glass of plain water; remain upright for 30 minutes. |
| Intravenous Bisphosphonates | Zoledronic Acid (Reclast) | Potent nitrogen-containing bisphosphonate administered via annual IV infusion. | Bypasses GI tract entirely; ideal for patients with GERD or oral intolerance. 15-minute annual infusion. |
| RANKL Monoclonal Antibody | Denosumab (Prolia) | Binds and neutralizes RANK-Ligand, preventing osteoclast maturation and survival. | Subcutaneous injection every 6 months. Crucial: Do NOT stop abruptly without bridging therapy to prevent rebound vertebral fractures. |
| PTH / PTHrP Receptor Agonists (Anabolic) | Teriparatide (Forteo), Abaloparatide (Tymlos) | Intermittent daily parathyroid hormone signaling stimulating new osteoblastic bone formation. | Daily subcutaneous injection for 18–24 months; builds substantial new cortical and trabecular bone in severe osteoporosis. |
| Dual-Action Sclerostin Inhibitor | Romosozumab (Evenity) | Monoclonal antibody blocking sclerostin: simultaneously increases bone formation and decreases resorption. | Monthly subcutaneous injections for 12 months; powerful rapid increase in bone mineral density. |
Bone-Building Nutrition & Mechanical Loading Protocol
When to Consult a Bone Health Specialist or Endocrinologist
- Suffer a bone fracture from a standing-height fall or minor trauma (Fragility Fracture)
- Experience a documented loss of height of >1.5 inches (4 cm) compared to young adult height
- Have been prescribed oral Prednisone or systemic corticosteroids for >3 consecutive months
- Have a DEXA scan T-score ≤ -2.5 or FRAX 10-year major fracture risk ≥ 20% / hip risk ≥ 3%
Frequently Asked Questions
Dr. Prasun Chatterjee, MBBS, MD (Geriatrics)
Professor & Head, Department of Geriatric Medicine, AIIMS New Delhi • MBBS, MD (Geriatric Medicine)Dr. Prasun Chatterjee is Professor in the Department of Geriatric Medicine at the All India Institute of Medical Sciences (AIIMS), New Delhi. A leading authority on healthy longevity, memory clinics, dementia care, and geriatric polypharmacy, he oversees clinical guidance on senior health and longevity.
References & Clinical Resources
- Camacho PM, Petak SM, Binkley N, et al.. Clinical Practice Guideline for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update (2020). [Access Resource Link] — Endocrine Practice. 26(Suppl 1):1-46
- US Preventive Services Task Force. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement (2018). [Access Resource Link] — JAMA. 319(24):2521-2531
- Cosman F, Crittenden DB, Adachi JD, et al.. Romosozumab Treatment in Postmenopausal Women with Osteoporosis (FRAME Trial) (2016). [Access Resource Link] — New England Journal of Medicine. 375(16):1532-1543
Related Healthcare Guides
Reader Reviews & Clinical Q&A
Real experiences, reader questions, and verified physician guidance.
At 72, I was concerned about muscle loss and fatigue. Implementing the protein distribution and resistance training suggestions here has significantly improved my balance and energy levels.
That is wonderful to hear, Gerald! Preserving lean muscle mass and motor unit recruitment through progressive resistance training is the foundation of healthy longevity.
The inclusion of the AGS Beers Criteria and anticholinergic risk scores makes this an invaluable educational asset for patients and families navigating polypharmacy.
Deprescribing and medication reconciliation are critical safety imperatives in geriatric care, Dr. Steven. Thank you for championing patient safety.